Puma Biotechnology INC (PBYI) Holder Sio Capital Management LLC Has Lowered Its Position by $6.28 Million

March 14, 2018 - By Marie Mckinney

Investors sentiment increased to 1.55 in Q3 2017. Its up 0.34, from 1.21 in 2017Q2. It is positive, as 19 investors sold PBYI shares while 41 reduced holdings. 41 funds opened positions while 52 raised stakes. 35.70 million shares or 3.15% more from 34.61 million shares in 2017Q2 were reported. Emerald Mutual Fund Advisers Trust, Pennsylvania-based fund reported 291,146 shares. Putnam Ltd Liability Co reported 0.01% stake. Illinois-based Guggenheim Ltd Company has invested 0.01% in Puma Biotechnology, Inc. (NASDAQ:PBYI). Proshare Advsrs Ltd Liability has invested 0% of its portfolio in Puma Biotechnology, Inc. (NASDAQ:PBYI). Franklin Res, California-based fund reported 831,500 shares. Pointstate Capital LP reported 414,010 shares. Barclays Public Limited Company has 0.02% invested in Puma Biotechnology, Inc. (NASDAQ:PBYI) for 187,549 shares. Vanguard Gp owns 2.55M shares or 0.01% of their US portfolio. Deutsche Comml Bank Ag owns 603,908 shares for 0.05% of their portfolio. Hanseatic Management holds 0% or 36 shares. California State Teachers Retirement Systems has invested 0.01% of its portfolio in Puma Biotechnology, Inc. (NASDAQ:PBYI). Citigroup holds 0% or 29,565 shares in its portfolio. Eam Investors Ltd Liability Com owns 23,196 shares or 0.37% of their US portfolio. Perceptive Advisors Ltd Com invested in 923,820 shares or 4.22% of the stock. Franklin Street Advsr Nc owns 22,000 shares for 0.43% of their portfolio.

Since September 29, 2017, it had 0 insider purchases, and 5 selling transactions for $3.20 million activity. $62,117 worth of Puma Biotechnology, Inc. (NASDAQ:PBYI) shares were sold by EYLER CHARLES R. 10,692 shares valued at $991,683 were sold by AUERBACH ALAN H on Monday, January 22. Lo Steven also sold $172,515 worth of Puma Biotechnology, Inc. (NASDAQ:PBYI) shares.

Sio Capital Management Llc decreased its stake in Puma Biotechnology Inc (PBYI) by 65.98% based on its latest 2017Q3 regulatory filing with the SEC. Sio Capital Management Llc sold 52,800 shares as the company’s stock declined 6.09% while stock markets rallied. The institutional investor held 27,221 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $3.26M, down from 80,021 at the end of the previous reported quarter. Sio Capital Management Llc who had been investing in Puma Biotechnology Inc for a number of months, seems to be less bullish one the $2.79B market cap company. The stock increased 0.61% or $0.45 during the last trading session, reaching $74.25. About 542,748 shares traded. Puma Biotechnology, Inc. (NYSE:PBYI) has risen 23.65% since March 14, 2017 and is uptrending. It has outperformed by 6.95% the S&P500.

Sio Capital Management Llc, which manages about $116.75 million and $192.73M US Long portfolio, upped its stake in Axovant Sciences Ltd (Put) by 3.61 million shares to 3.64M shares, valued at $25.03 million in 2017Q3, according to the filing.

Analysts await Puma Biotechnology, Inc. (NASDAQ:PBYI) to report earnings on May, 9. They expect $-0.72 earnings per share, up 63.45 % or $1.25 from last year’s $-1.97 per share. After $-1.71 actual earnings per share reported by Puma Biotechnology, Inc. for the previous quarter, Wall Street now forecasts -57.89 % EPS growth.

More news for Puma Biotechnology, Inc. (NASDAQ:PBYI) were recently published by: Businesswire.com, which released: “Puma Biotechnology Receives Results of CHMP Formal Decision for Neratinib for …” on February 23, 2018. Businesswire.com‘s article titled: “Puma Biotechnology to Present at Cowen’s Annual Healthcare Conference” and published on March 06, 2018 is yet another important article.

Puma Biotechnology, Inc. (NASDAQ:PBYI) Ratings Coverage

Among 11 analysts covering Puma Biotechnology Inc (NYSE:PBYI), 9 have Buy rating, 0 Sell and 2 Hold. Therefore 82% are positive. Puma Biotechnology Inc had 60 analyst reports since August 27, 2015 according to SRatingsIntel. The company was maintained on Thursday, October 5 by Citigroup. JP Morgan maintained it with “Overweight” rating and $89 target in Tuesday, March 29 report. As per Wednesday, January 24, the company rating was maintained by Citigroup. The firm has “Market Perform” rating given on Tuesday, May 23 by Cowen & Co. Credit Suisse maintained the stock with “Outperform” rating in Thursday, September 22 report. The stock of Puma Biotechnology, Inc. (NASDAQ:PBYI) has “Buy” rating given on Tuesday, July 18 by Credit Suisse. Stifel Nicolaus maintained it with “Buy” rating and $11000 target in Wednesday, August 9 report. Cowen & Co downgraded the shares of PBYI in report on Wednesday, January 24 to “Market Perform” rating. Credit Suisse maintained Puma Biotechnology, Inc. (NASDAQ:PBYI) rating on Monday, September 11. Credit Suisse has “Outperform” rating and $136 target. The firm earned “Neutral” rating on Thursday, September 3 by Citigroup.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: